These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 35799213)

  • 1. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.
    Liu Y; Li Y; Wang Y; Lin C; Zhang D; Chen J; Ouyang L; Wu F; Zhang J; Chen L
    J Hematol Oncol; 2022 Jul; 15(1):89. PubMed ID: 35799213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
    Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
    Zhang C; Tan C; Ding H; Xin T; Jiang Y
    Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors.
    Cheng K; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(13):2540-2564. PubMed ID: 32407259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy.
    Liu XJ; Zhao HC; Hou SJ; Zhang HJ; Cheng L; Yuan S; Zhang LR; Song J; Zhang SY; Chen SW
    Bioorg Chem; 2023 Apr; 133():106425. PubMed ID: 36801788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
    Sharma PS; Sharma R; Tyagi T
    Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.
    Paillasse MR; Esquerré M; Bertrand FA; Poussereau-Pomié C; Pichery M; Visentin V; Gueguen-Dorbes G; Gaujarengues F; Barron P; Badet G; Briaux A; Ancey PB; Sibrac D; Erdociain E; Özcelik D; Meneyrol J; Martin V; Gomez-Brouchet A; Selves J; Rochaix P; Battistella M; Lebbé C; Delord JP; Dol-Gleizes F; Bono F; Blanc I; Alam A; Hunneyball I; Whittaker M; Fons P
    Cancer Res Commun; 2022 Nov; 2(11):1504-1519. PubMed ID: 36970050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

  • 10. Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions.
    Malekan M; Ebrahimzadeh MA
    Curr Top Med Chem; 2022; 22(11):891-920. PubMed ID: 35260067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.
    Chimote G; Sreenivasan J; Pawar N; Subramanian J; Sivaramakrishnan H; Sharma S
    Drug Des Devel Ther; 2014; 8():1107-23. PubMed ID: 25170251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
    Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents.
    Yousefian M; Ghodsi R
    Arch Pharm (Weinheim); 2020 Dec; 353(12):e2000022. PubMed ID: 32885522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
    Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
    Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular design and clinical development of VEGFR kinase inhibitors.
    Zhong H; Bowen JP
    Curr Top Med Chem; 2007; 7(14):1379-93. PubMed ID: 17692027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.